Cargando…
CCL2 as a potential therapeutic target for clear cell renal cell carcinoma
We previously reported that the pVHL‐atypical PKC‐JunB pathway contributed to promotion of cell invasiveness and angiogenesis in clear cell renal cell carcinoma (ccRCC), and we detected chemokine (C‐C motif) ligand‐2 (CCL2) as one of downstream effectors of JunB. CCL2 plays a critical role in tumori...
Autores principales: | Arakaki, Ryuichiro, Yamasaki, Toshinari, Kanno, Toru, Shibasaki, Noboru, Sakamoto, Hiromasa, Utsunomiya, Noriaki, Sumiyoshi, Takayuki, Shibuya, Shinsuke, Tsuruyama, Tatsuaki, Nakamura, Eijiro, Ogawa, Osamu, Kamba, Tomomi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5083746/ https://www.ncbi.nlm.nih.gov/pubmed/27666332 http://dx.doi.org/10.1002/cam4.886 |
Ejemplares similares
-
Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
por: Shibasaki, Noboru, et al.
Publicado: (2015) -
Functional and genomic characterization of patient‐derived xenograft model to study the adaptation to mTORC1 inhibitor in clear cell renal cell carcinoma
por: Sakamoto, Hiromasa, et al.
Publicado: (2020) -
Detection of von Hippel‐Lindau gene mutation in circulating cell‐free DNA for clear cell renal cell carcinoma
por: Sumiyoshi, Takayuki, et al.
Publicado: (2021) -
Extracellular vesicles secreted from bone metastatic renal cell carcinoma promote angiogenesis and endothelial gap formation in bone marrow in a time-dependent manner in a preclinical mouse model
por: Takeda, Masashi, et al.
Publicado: (2023) -
Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer
por: Sumiyoshi, Takayuki, et al.
Publicado: (2019)